|Articles|January 15, 2008

BAK linked to ocular surface damage in animal studies

Prostaglandin analogues preserved with benzalkonium chloride (BAK) can cause more extensive loss of goblet cells and a breakdown of cell-cell adhesions, which could increase the risk of ocular surface disease, according to findings from a pair of studies conducted in rabbits.

Don’t miss out—get OT Europe updates delivered straight to your inbox.

BAK linked to ocular surface damage in animal studies

Related Content

Phaco-GSL outperforms in acute angle-closure glaucoma over chronic cases, 2-year study finds

Similarity in corneal biomechanics between 2 major glaucoma types: More alike than expected?

EGS 2026: Glaucoma surgery, imaging and neuroscience take centre stage in Brussels

First commercial FLIGHT procedures performed as ViaLase begins European launch

Rethinking SLT: From pressure reduction to biological activation

Latest CME

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

MacTel Decoded: Rethinking Conventional Approaches With Novel Neuroprotective Strategies

Treatment Optimization in the Evolving Anti-VEGF Era

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

(COPE) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

(CME) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

(CME Track) Embracing the Interventional Glaucoma Mindset: A Paradigm Shift in Contemporary Glaucoma Management

(COPE Track) Embracing the Interventional Glaucoma Mindset: A Paradigm Shift in Contemporary Glaucoma Management

(CME Track) Cutting-Edge Care in Neovascular Retinal Disease: Expert Approaches to Selection and Interval Extension

(COPE Track) Next-Generation Solutions for nAMD and DME: Bridging Evidence and Practice Gaps in Disease Management

(COPE Track) Emerging Therapeutic Advancements in Dry Eye Disease Management

Trending on Eye Care Network - Ophthalmology Times

Retinal imaging as a window into atrial fibrillation

The Wills Retina Report: Mapping gene therapy for wet AMD with Carl D. Regillo, MD, and Allen C. Ho, MD

Think outside the cone: Applying the Gulani Keratoconus Classification

Johnson & Johnson spotlights contrast data, 1 million TECNIS implants, and SmartLOAD delivery

The One Thing: Earlier AMD intervention, steroid education, and healthcare waste | Episode 4